India, May 6 -- EyePoint Pharmaceuticals, Inc. (EYPT) Monday reported that its phase 2 trial of Duravyu in non-proliferative diabetic retinopathy failed to meet primary endpoint. Shares of the company plunged over 34% in the morning traded, following the news.
The data demonstrated that Duravyu has a biologic effect in patients with NPDR with a favorable safety and tolerability profile, however the trial did not meet the pre-specified primary endpoint.
"The objective of the PAVIA trial was, for the first time, to evaluate DURAVYU as a potential treatment in a non-proliferative diabetic patient population," said Jay Duker, Chief Executive Officer of EyePoint Pharmaceuticals. "Although the trial did not meet the pre-specified primary endpoi...